Juvenile Idiopathic Arthritis - A Pipeline Analysis Report

Overview of the drug development for juvenile idiopathic arthritis

Juvenile Idiopathic Arthritis (JIA) is also known as pediatric rheumatic disease and is one of the most common type of arthritis found in children under the age of 16 years. Some children may experience symptoms for only a few months, while others have symptoms for the rest of their lives. JIA affects the body tissues of the child, leading to painful inflammation in joints. Currently, there is no cure for JIA, however, with early diagnosis and treatment, the remission of JIA is under control. According to the NIH, the incidences of JIA in North America and Europe is estimated to be 4-16 in 10,000 children. In the US alone, one in 1,000 children is affected, which is estimated to be 294,000 children. Globally, the incidence rate of JIA varies across different populations and ethnic groups. Consequently, the rising incidences of the disease are further likely to proliferate the drug development for juvenile idiopathic arthritis.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for juvenile idiopathic arthritis (JIA). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of juvenile idiopathic arthritis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AbbVie
• Adello Biologics
• Novartis
• Pfizer
• Regeneron

Therapeutic assessment of the drug development for juvenile idiopathic arthritis by route of administration

• Subcutaneous
• Oral
• Intravenous
• Intravenous and subcutaneous

The subcutaneous route of administration (ROA) involves the application of the drug directly into the subcutis, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for juvenile idiopathic arthritis by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development for juvenile idiopathic arthritis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for juvenile idiopathic arthritis?
• What are the companies that are currently involved in the development of drug molecules for juvenile idiopathic arthritis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.